DEFA14A: Performant Healthcare Merger Update Amid Lawsuits

Performant Healthcare issues a proxy supplement addressing shareholder lawsuits and clarifying merger valuation details for its acquisition by Machinify.

Summary

• Performant Healthcare, Inc. (Performant) filed a supplement to its definitive proxy statement for a Special Meeting of Shareholders on October 17, 2025, concerning its merger with Continental Buyer, Inc. (Machinify).
• The supplement was issued in response to two shareholder complaints and ten demand letters alleging material omissions or misstatements in the original proxy statement.
• Performant denies the allegations but made voluntary disclosures to avoid potential delays and expenses related to the proposed merger.
• The board of directors unanimously continues to recommend voting FOR the merger proposals.
• Supplemental disclosures include details on standstill provisions in non-disclosure agreements with potential bidders (Machinify, Party A, Party C, Party B, Party X), clarifying that some did not restrict topping bids.
• Truist Securities, Inc.'s selected transactions analysis indicated implied values of $1.78 to $2.93 per share (based on LTM EBITDA of $11.8 million) and $1.94 to $3.27 per share (based on LTM Revenue of $132.3 million) as of May 31, 2025.
• Truist's discounted cash flow analysis indicated an implied value range of $4.26 to $7.16 per share and an implied enterprise value of $367 million to $617 million.
• These implied values are compared to the merger consideration of $7.75 per share and the July 25, 2025 closing price of $3.63.

Sentiment

Score: 7

Explanation: The filing addresses legal challenges but reaffirms the board's unanimous support for a merger offering a significant premium over pre-announcement prices and valuation ranges. The voluntary disclosures aim to mitigate risks and ensure the merger proceeds, which is positive for shareholders seeking the merger consideration, despite the underlying litigation.

Positives

• The board of directors unanimously recommends voting FOR the merger, indicating strong internal support for the transaction.
• The merger consideration of $7.75 per share is significantly higher than the implied value ranges from Truist's selected transactions analysis ($1.78-$2.93 and $1.94-$3.27 per share) and discounted cash flow analysis ($4.26-$7.16 per share).
• The merger consideration of $7.75 per share represents a substantial premium over the $3.63 closing price per Company Share on July 25, 2025.
• Standstill provisions with other parties (Party A, Party C, Party B, Party X) did not restrict them from submitting potential topping bids, suggesting a competitive process was possible.

Negatives

• The company is facing two shareholder lawsuits and ten demand letters alleging material omissions or misstatements in the proxy statement.
• The company is making voluntary disclosures to avoid potential delays and expenses associated with defending against these legal challenges, even while denying their merit.

Risks

• Potential future claims or litigation in connection with the proposed Merger.
• Potential impact of litigation on the timing and ability of the parties to consummate the proposed Merger.
• Expenses associated with defending against the Complaints or any potential lawsuit.
• Risks noted in the CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS section of the original Proxy Statement.
• Risks related to Performant's business as detailed in its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and Quarterly Report on Form 10-Q for the quarter ended June 30, 2025.

Future Outlook

The filing primarily focuses on past events and current legal challenges related to the merger. It reiterates the board's unanimous recommendation for the merger and references forward-looking statements from previous filings regarding anticipated benefits, future plans, and financial performance, but does not introduce new forward-looking guidance.

Management Comments

• "The Company believes that the alleged omissions and misstatements are immaterial and that no further disclosure is required by applicable statute, rule, regulation, or law beyond that already contained in the Proxy Statement."
• "Solely in order to avoid the risk that the Complaints or the demand letters may delay or otherwise adversely affect the consummation of the proposed Merger, and to minimize the expense and distraction of defending against the Complaints or any potential lawsuit that may arise as a result of the demand letters, the Company has determined to voluntarily make certain supplemental disclosures."
• "Nothing in this Supplement shall be deemed an admission of the legal necessity or materiality under applicable laws of the supplemental disclosures. To the contrary, the Company specifically denies any and all allegations that any additional disclosure was or is required."
• "The Company's board of directors continues to recommend unanimously that you vote FOR the proposals being considered at the Special Meeting."

Industry Context

This filing reflects a common occurrence in M&A transactions where shareholder litigation arises, often alleging inadequate disclosures or unfair valuation. The voluntary supplemental disclosures, despite denying the merit of the claims, are a strategic move to mitigate legal risks and ensure the timely completion of the merger, a practice frequently observed in the U.S. M&A landscape to avoid protracted legal battles. The healthcare sector, particularly companies involved in specialized services like Performant, often sees consolidation efforts, and such mergers are subject to intense scrutiny from shareholders and regulators.

Comparison to Industry Standards

• The use of selected transactions analysis and discounted cash flow analysis by Truist Securities, Inc. aligns with standard valuation methodologies employed by financial advisors in M&A transactions across industries.
• The implied LTM EBITDA multiples (12.8x to 21.2x) and LTM Revenue multiples (1.2x to 2.1x) from the selected transactions analysis, and the implied terminal LTM EBITDA multiple (5.1x to 8.6x) from the DCF, would typically be compared against recent M&A transactions for comparable healthcare services companies to assess their competitiveness. Without specific comparable company data in the filing, a direct assessment against global benchmarks is limited. However, the fact that the merger consideration of $7.75 per share is significantly above these implied valuation ranges suggests a premium is being paid, which can be attractive to shareholders.

Legal Proceedings

• Jones v. Performant Healthcare, Inc., et al., No. 655683/2025 (N.Y. Sup. Ct. filed Sept. 24, 2025), alleging omissions or misstatements in the Proxy Statement.
• Wright v. Performant Healthcare, Inc., et al., No. 655719/2025/2025 (N.Y. Sup. Ct. filed Sept. 25, 2025), alleging omissions or misstatements in the Proxy Statement.
• Ten other purported shareholders sent demand letters to the Company making similar allegations and demands.

Stakeholder Impact

• Shareholders: Potential to receive $7.75 per share if the merger is approved and consummated, representing a significant premium. Facing a vote on the merger and potential impact from ongoing litigation.
• Company (Performant): Incurs expenses and distraction from defending against shareholder complaints, but aims to proceed with the strategic merger.
• Acquirer (Machinify): The merger process is proceeding, but faces potential delays due to shareholder litigation.

Next Steps

• Shareholders to vote on the merger proposals at the Special Meeting on October 17, 2025.
• Consummation of the proposed Merger, subject to terms and conditions of the Merger Agreement.
• Potential defense against existing or future shareholder complaints/demand letters.

Key Dates

Recommendation

The merger consideration of $7.75 per share offers a substantial premium over the pre-announcement share price of $3.63 and exceeds the valuation ranges derived by Truist Securities, Inc. The board unanimously recommends the merger, and the company is taking steps to mitigate legal risks to ensure its completion. For investors, this represents an opportunity to realize a significant gain upon merger close.

Keywords

Merger, Acquisition, Proxy Statement, Shareholder Lawsuit, SEC Filing, Healthcare, Performant, Machinify, Valuation, Special Meeting, Corporate Governance, Standstill Agreement, Discounted Cash Flow, EBITDA, Revenue